BATS · NVOH
Healthcare · Medical - Pharmaceuticals
$23.43
Up+$0.32 (+1.37%)
Updated Sep 14, 2026, 7:15 PM
SID Score
3.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
NVOH closed at $23.43 after 19 trading sessions, down 4.07% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $23.4261 | $23.4261 | $23.4261 | $23.4261 | 285.28 |
| Sep 10, 2026 | $24.16 | $24.17 | $23.954 | $23.954 | 796.89 |
| Sep 9, 2026 | $24.40 | $24.52 | $24.1612 | $24.1612 | 1.7K |
| Sep 8, 2026 | $24.63 | $24.78 | $24.51 | $24.5207 | 853.19 |
| Sep 4, 2026 | $25.10 | $25.2595 | $25.05 | $25.2595 | 1K |
| Sep 3, 2026 | $25.85 | $25.85 | $25.38 | $25.6877 | 2.98K |
| Sep 2, 2026 | $25.49 | $25.49 | $25.28 | $25.4618 | 1.14K |
| Sep 1, 2026 | $24.73 | $24.73 | $24.5091 | $24.5091 | 293.56 |
| Aug 31, 2026 | $24.50 | $24.69 | $24.50 | $24.5859 | 969.08 |
| Aug 28, 2026 | $24.96 | $24.96 | $24.73 | $24.7751 | 6.93K |
| Aug 27, 2026 | $24.85 | $25.02 | $24.75 | $24.9897 | 1.64K |
| Aug 26, 2026 | $25.69 | $25.69 | $25.4775 | $25.4775 | 592.38 |
| Aug 25, 2026 | $25.95 | $26.37 | $25.70 | $26.37 | 1.53K |
| Aug 24, 2026 | $25.33 | $25.35 | $25.33 | $25.35 | 499.03 |
| Aug 21, 2026 | $25.24 | $25.36 | $25.21 | $25.2397 | 986.98 |
| Aug 20, 2026 | $25.00 | $25.05 | $24.3201 | $24.9612 | 1.04K |
| Aug 19, 2026 | $25.30 | $25.42 | $25.0553 | $25.0553 | 1.31K |
| Aug 18, 2026 | $24.63 | $24.8729 | $24.63 | $24.8729 | 318.6 |
| Aug 17, 2026 | $24.56 | $24.66 | $24.4193 | $24.4193 | 725.64 |
The latest Smart Investors Daily articles mentioning NVOH.
NVOH research
Company profile and research snapshot.
The series, under normal circumstances, invests at least 95% of its net assets in American Depositary Receipts (“ADRs”) of the Novo Nordisk A/S (B Shares) (the “Company”). The series will not invest directly in the company. The fund is non-diversified.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
The Motley Fool · Feb 26, 2025
Viking Therapeutics (VKTX) is a biotech company developing a weight loss drug candidate that has shown promising results in clinical trials. The company aims to launch a phase 3 trial for the injectable version of VK2735 in the second quarter. Despite recent stock declines, the article suggests that Viking could be a good buy considering the high-growth weight loss drug market opportunity and the company's progress.
The Motley Fool · Feb 6, 2025
The article discusses Disney's (DIS) first-quarter earnings report, providing an overview of the company's performance and financial results.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NVOH.
No results
No recent SID articles mention NVOH.
